Endurance Wealth Management’s Mirum Pharmaceuticals MIRM Stock Holding History

Endurance Wealth Management’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$50K	Hold	1,954	–	–	0.01%	336
2023 Q1	$47K	Hold	1,954	–	–	0.01%	353
2022 Q4	$38K	Buy	1,954 +1,254	+179%	+$24.8K	0.01%	359
2022 Q3	$15K	Hold	700	–	–	﹤0.01%	439
2022 Q2	$14K	Hold	700	–	–	﹤0.01%	459
2022 Q1	$15K	Hold	700	–	–	﹤0.01%	485
2021 Q4	$11K	Hold	700	–	–	﹤0.01%	501
2021 Q3	$18K	Hold	700	–	–	﹤0.01%	463
2021 Q2	$10K	Hold	700	–	–	﹤0.01%	522
2021 Q1	$14K	Hold	700	–	–	﹤0.01%	499
2020 Q4	$12K	Buy	+700	New	+$13.8K	﹤0.01%	473

Other funds holding MIRM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

RVM

RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Endurance Wealth Management's MIRM Position: Q2 2023 in Review

Endurance Wealth Management held its Mirum Pharmaceuticals (MIRM) position steady in Q2 2023 at 1,954 shares worth $50K. The position accounts for 0.01% of the portfolio, ranked #336.

Endurance Wealth Management first reported a position in MIRM in Q4 2020 and has held it in 11 quarters since. 146 funds tracked by Wall St. Rank hold MIRM as of Q2 2023.

Endurance Wealth Management held 1,954 shares of Mirum Pharmaceuticals worth $50K as of Q2 2023.
Endurance Wealth Management left its Mirum Pharmaceuticals share count unchanged in Q2 2023.
Mirum Pharmaceuticals made up 0.01% of Endurance Wealth Management's portfolio in Q2 2023, its #336 holding.
Endurance Wealth Management first reported a position in Mirum Pharmaceuticals in Q4 2020 and has held it in 11 quarters since.
146 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2023.

Based on Endurance Wealth Management's 13F filing for Q2 2023, filed 9 Aug 2023.